Howie and Harlan discuss Dr. Vinay Prasad's departure from the FDA after a backlash against his decisions on Sarepta's Duchenne muscular dystrophy gene therapy. Also examined: AI in clinical settings, changes in NIH grantmaking, and the 60th anniversary of Medicare and Medicaid.

Links:

Sarepta and the FDA

"STAT breaks down the confusing, heartbreaking Sarepta saga"

"Sarepta Therapeutics' Duchenne therapy faces 'arduous' path back to market, senior FDA official says"

"For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak"

"FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault"

"FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients"

"FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients"

"Controversial FDA official Dr. Vinay Prasad departs agency"

"Top F.D.A. Vaccine Official Resigns, Citing Kennedy's 'Misinformation and Lies'"

"Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag"

"Timeline: The Rise and Fall of Vioxx"